Stocks Health care CGEM
NASDAQ · Health careCullinan Therapeutics, Inc. (CGEM)
It posted a net loss of $204.7M. In fiscal 2025 capital spending exceeded operating cash flow by $175.8M. At June 30, 2026 it held $78.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Key facts about Cullinan Therapeutics, Inc.
- Net worth
- Cullinan Therapeutics, Inc. has a market value (market cap) of $754.9M at the latest share price, and shareholders' equity of $321.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $175.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Cullinan Therapeutics, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
What Cullinan Therapeutics, Inc. does
Cullinan Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CGEM.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$219.9M | n/a | -$175.8M |
| 2024 | n/a | -$167.4M | n/a | -$145.3M |
| 2023 | n/a | -$153.2M | -$3.69 | -$134.5M |
| 2022 | $0 | $111.2M | $2.38 | -$127.8M |
| 2021 | $18.9M | -$65.6M | -$1.52 | -$43.4M |
| 2021 | $0 | -$51.8M | -$2.60 | -$29.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Cullinan Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 4, 2026
- October 2, 2026
- September 24, 2026
- September 14, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 13, 2026
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026
Insider trades
What the people running Cullinan Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $829.8K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 5, 2026 | Michaelson JenniferChief Scientific Officer | Exercised options | 3,805 | $16.4K |
| November 5, 2026 | Michaelson JenniferChief Scientific Officer | Soldpre-planned (10b5-1) | 4,000 | $49.4K |
| September 8, 2026 | Michaelson JenniferChief Scientific Officer | Exercised options | 4,000 | $17.2K |
| September 8, 2026 | Michaelson JenniferChief Scientific Officer | Soldpre-planned (10b5-1) | 8,000 | $172.6K |
| August 13, 2026 | Michaelson JenniferChief Scientific Officer | Exercised options | 30,000 | $129K |
| August 13, 2026 | Michaelson JenniferChief Scientific Officer | Soldpre-planned (10b5-1) | 30,000 | $607.8K |
| July 6, 2026 | Michaelson JenniferChief Scientific Officer | Exercised options | 4,000 | $17.2K |
| July 6, 2026 | Michaelson JenniferChief Scientific Officer | Soldpre-planned (10b5-1) | 8,000 | $142.6K |
Who owns CGEM
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Bvf Partners L P13G, passive with 9 related filers | 9.99% | August 14, 2026 |
| LYNX1 Capital Management LP13G, passive with 1 related filers | 9.8% | November 14, 2025 |
| T. Rowe Price Associates, Inc.13G, passive | 6.2% | August 14, 2026 |
| Kynam Capital Management, LP13G, passive with 2 related filers | 5.27% | March 4, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 184 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Mpm Bioimpact LLC | 9,731,341 | +2,083,073 |
| Lynx1 Capital Management LP | 8,963,500 | 0 |
| Bvf Inc | 5,750,683 | 0 |
| BlackRock, Inc. | 5,232,766 | +782,800 |
| State Street Corp | 3,668,627 | +1,124,512 |
| Kynam Capital Management, LP | 3,114,132 | 0 |
| Vanguard Capital Management LLC | 2,614,066 | +131,032 |
| Rtw Investments, LP | 2,364,347 | +658,387 |
| Siren, L.L.C. | 1,893,410 | +700,000 |
| Geode Capital Management, LLC | 1,547,309 | +179,041 |
| Blue Owl Capital Holdings LP | 1,539,764 | -370,000 |
| Venrock Adviser, LLC | 1,379,965 | 0 |
| Boothbay Fund Management, LLC | 1,082,611 | -30,192 |
| Dimensional Fund Advisors LP | 1,046,694 | +140,666 |
| Goldman Sachs Group Inc | 1,001,598 | +546,149 |
| Affinity Asset Advisors, LLC | 875,760 | +94,500 |
| Vanguard Portfolio Management LLC | 738,741 | +186,188 |
| Boone Capital Management LLC | 704,442 | new |
| Elmind Capital, LP | 690,000 | +160,000 |
| Morgan Stanley | 629,035 | +39,552 |
Insiders
5 insiders reported holding 967,900 shares in total, about $11.4M at the last price.
| Holder | Shares |
|---|---|
| Ahmed NadimPresident and CEO, Director | 390,803 |
| Jones Jeffrey AlanChief Medical Officer | 159,968 |
| Michaelson JenniferChief Scientific Officer | 158,649 |
| Sumer Jacquelyn LChief Legal Officer | 130,559 |
| Fenton Mary KayChief Financial Officer | 127,921 |
Questions about CGEM
What does Cullinan Therapeutics, Inc. do?
Cullinan Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as CGEM. Its shares trade on NASDAQ under the ticker CGEM.
What is Cullinan Therapeutics, Inc.'s net worth?
Cullinan Therapeutics, Inc. has a market value (market cap) of $754.9M at the latest share price, and shareholders' equity of $321.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Cullinan Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $204.7M.
When did Cullinan Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from November 9, 2026.
When is Cullinan Therapeutics, Inc.'s next earnings report?
Cullinan Therapeutics, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare CGEM with
Follow CGEM
Get an email when Cullinan Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Cullinan Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.